EyePoint Pharmaceuticals, Inc. (EYPT)
| Market Cap | 299.81M |
| Revenue (ttm) | 37.33M |
| Net Income (ttm) | -105.96M |
| Shares Out | 34.98M |
| EPS (ttm) | -2.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 37,810 |
| Open | 8.50 |
| Previous Close | 8.45 |
| Day's Range | 8.39 - 8.70 |
| 52-Week Range | 2.19 - 15.63 |
| Beta | 1.30 |
| Analysts | Strong Buy |
| Price Target | 32.20 (+274.42%) |
| Earnings Date | Nov 1, 2023 |
About EYPT
EyePoint Pharmaceuticals, Inc. focuses on developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The company's pipeline leverages its proprietary erodible Durasert E technology for sustained intraocular drug delivery, including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment, which is in Phase 2 clinical trials. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc.... [Read more]
Financial Performance
In 2022, EYPT's revenue was $41.40 million, an increase of 12.09% compared to the previous year's $36.94 million. Losses were -$102.25 million, 75.0% more than in 2021.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for EYPT stock is "Strong Buy." The 12-month stock price forecast is $32.2, which is an increase of 274.42% from the latest price.
News
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of pati...
EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023
- Interim analysis of masked data shows EYP-1901 is well tolerated with no reported drug-related ocular or systemic serious adverse events in Phase 2 PAVIA clinical trial in non-proliferative diabetic...
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
WATERTOWN, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the live...
EyePoint Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
WATERTOWN, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients w...
EyePoint Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Developments
–Phase 2 DAVIO 2 clinical trial evaluating EYP-1901 in wet age-related macular degeneration remains on track to report topline data in December 2023 –
EyePoint Pharmaceuticals Presents Interim Masked Safety Data and Patient Baseline Characteristics for DAVIO 2 Clinical Trial at OIS Retina Innovation Summit
Interim safety data from the Phase 2 DAVIO 2 trial continues to demonstrate EYP-1901 is well tolerated with no reported drug-related ocular or systemic SAEs
EyePoint Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 2, 2023
WATERTOWN, Mass., July 26, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients w...
EyePoint Pharmaceuticals Announces Chief Executive Officer Transition
– Jay S. Duker, M.D., Previously President and Chief Operating Officer, Appointed President and Chief Executive Officer –
EyePoint Pharmaceuticals Completes Enrollment in Phase 2 PAVIA Clinical Trial of EYP-1901 in Non-Proliferative Diabetic Retinopathy
– Significant investigator and patient interest drove strong recruitment of 77 patients exceeding the 60 patient target –
EyePoint Pharmaceuticals to Present at the Jefferies Healthcare Conference
WATERTOWN, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients wi...
EyePoint Pharmaceuticals Announces Sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 Million Cash Plus Royalties
–$75M paid at closing with an additional $7.5M payable in equal quarterly installments in 2024 – All outstanding bank debt retired and expected cash runway extended into 2025 – EyePoint well-capitaliz...
EyePoint Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Developments
– Completed enrollment in the oversubscribed Phase 2 DAVIO 2 clinical trial evaluating EYP-1901 in wet age-related macular degeneration (AMD); topline data anticipated in 4Q 2023
EyePoint Pharmaceuticals to Report First Quarter 2023 Financial Results on May 3, 2023
WATERTOWN, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients ...
EyePoint Pharmaceuticals Completes Enrollment in Oversubscribed Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for Maintenance Treatment of Wet AMD
- Significant investigator and patient interest drove strong recruitment, exceeding enrollment goals
EyePoint Pharmaceuticals Announces Upcoming Data Presentations at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
- Positive neuroprotective effect of vorolanib, the active drug in EYP-1901, in a widely validated retinal detachment model demonstrates a potential new mechanism of action for the treatment of retina...
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Developments
– Phase 2 DAVIO 2 clinical trial in wet AMD on track with topline data anticipated by year-end 2023 –
EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 2, 2023
WATERTOWN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the...
EyePoint Investor Alert
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile C...
EyePoint Shareholder Action Reminder
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile C...
EYEPOINT SHAREHOLDER ACTION REMINDER
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him Directly To Discuss Their Options NEW YORK , Jan. 28, 2023 /PRNe...
EyePoint Pharmaceuticals Enters Lease Agreement for the Construction of a Commercial Manufacturing Facility for Global Product Supply of EYP-1901 and YUTIQ
– State-of-the-art cGMP manufacturing facility to be built in Northbridge, Massachusetts –
EYEPOINT INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him Directly To Discuss Their Options
NEW YORK , Jan. 22, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against EyePoint Pharmaceuticals ("Eyepoint" or the "Company") ...
EyePoint Pharmaceuticals Provides Business Update and Key 2023 Clinical Timelines
– Topline data for Phase 2 DAVIO 2 clinical trial in wet AMD expected in 4Q 2023 –
EyePoint Pharmaceuticals Promotes Jay S. Duker, M.D.
Dr. Duker has served as EyePoint's Chief Operating Officer since November 2021 Dr. Duker has served as EyePoint's Chief Operating Officer since November 2021
EYEPOINT INVESTOR ALERT
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him Directly To Discuss Their Options NEW YORK , Dec. 25, 2022 /PRNe...